Axolabs (Nuvisan)

Kulmbach, Germany
Find alternatives to Axolabs (Nuvisan) for Oligonucleotide →
3 confirmed programs · 2 sponsors · Last scored 2026-10-29
71.8
Signal Score
✓ FDA Inspections (4) ✓ Clinical Trials (3) ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP ✓ HC GMP (12)

Quick Facts: Axolabs (Nuvisan)

Signal Score
71.8/100 (as of 2026-10-29)
Quality Compliance
96.8/100
Headquarters
Kulmbach, Germany
Modalities
Oligonucleotide
Active Programs
3 confirmed from ClinicalTrials.gov across 2 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Axolabs (Nuvisan)

Pure-play CDMO.

Signal Score & Pillar Breakdown

Quality Compliance 96.8
FDA Inspections4 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2025-01-16)
Most Recent HC OutcomeCompliant · 2025-01-16
HC Attribution12 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Operations 55.0
3 active programs across 2 sponsors
Modalities: Oligonucleotide
Source: ClinicalTrials.gov
3 active programs across 2 sponsors · Modalities: Oligonucleotide
Programs 3
Sponsors2
ModalitiesOligonucleotide
3 active programs across 2 sponsors
Modalities: Oligonucleotide
Source: ClinicalTrials.gov facility matching
NCT03492437 Effect of Tepotinib on the PK of the P-gp Substrate... PHASE1 Completed
NCT03531762 Effect of a Proton Pump Inhibitor on the PK of Tepotinib PHASE1 Completed
NCT01258660 Assessment of the Pharmacodynamic Effect on Plasma Folate and... PHASE1 Completed
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability 68.0
Parent company: Nuvisan
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Nuvisan
Financial assessment: 68.0/100
Capacity 53.0
1 manufacturing site: Kulmbach, DE
Modalities: Oligonucleotide
Capacity assessment: 53.0/100
Sites: Kulmbach, DE
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: Kulmbach, DE
Modalities: Oligonucleotide
Capacity assessment: 53.0/100

Axolabs (Nuvisan) FDA Inspection History

2025-01
2024-10
2023-04
2022-01
NAI VAI OAI
Date Site Type 483 citations posted Classification
2025-01-16
Nuvisan GmbH
Waltrop Company-level
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2024-10-17
Nuvisan GmbH
Neu-Ulm Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2023-04-26
NUVISAN GmbH
Gauting Company-level
Bioresearch Monitoring Not posted Voluntary Action Indicated (VAI)
2022-01-11
Nuvisan GmbH
Waltrop Company-level
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
Source: FDA Data Dashboard · Retrieved Nov 21, 2026

Hiring Activity Beta

Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data. This company's careers site asks automated readers not to collect it (robots.txt), and we respect that.
Source: smartrecruiters · Checked Nov 20, 2026

Frequently Asked Questions About Axolabs (Nuvisan)

How many FDA inspections does Axolabs (Nuvisan) have on record?
CDMO Signal tracks 4 FDA inspections for Axolabs (Nuvisan), sourced from the FDA inspection database. See the full inspection history above.
Has Axolabs (Nuvisan) received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Axolabs (Nuvisan).
How many clinical programs is Axolabs (Nuvisan) linked to?
Axolabs (Nuvisan) is associated with 3 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Axolabs (Nuvisan)'s CDMO Signal Score?
Axolabs (Nuvisan) has a Signal Score of 72/100, based on quality, operations, financial stability, and capacity data.
Evaluating Axolabs (Nuvisan) for a manufacturing program?
Use the free AI matchmaker to compare Axolabs (Nuvisan) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Oligonucleotide CDMOs →

Similar CDMOs

BioSpring
Frankfurt am Main, Germany
Oligonucleotide, mRNA/LNP
Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
Signal Score: 83.5
Oligonucleotide, Biologics, AAV
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score: 83.1
mRNA, Oligonucleotide, Biologics
Kaneka Eurogentec
Seraing, BE
Signal Score: 81.6
mRNA, Plasmid, Oligonucleotide
Nitto Denko Avecia
Milford, MA
Signal Score: 80.3
Oligonucleotide, mRNA

Compare Axolabs (Nuvisan) with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Axolabs (Nuvisan)
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.